Demand for weight-loss drugs highlights key factors for brand owners tackling opportunistic infringers
As Novo Nordisk and Eli Lilly work overtime to meet soaring demand for their popular diabetes and obesity drugs, trademark experts weigh in on what brand owners can do when opportunists take advantage of supply issues.
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the WTR experts.